Brief: NGM Bio Announces Clinical Trial Collaboration With Merck Related To Ongoing Phase 1/2 Trial Of NGM707 In Combination With Merck’s KEYTRUDA
06/12/2021 15:31
Dec 6 (Reuters) - NGM Biopharmaceuticals Inc NGM.O :
* NGM BIO ANNOUNCES CLINICAL TRIAL COLLABORATION WITH MERCK
RELATED TO ONGOING PHASE 1/2 TRIAL OF NGM707, AN ILT2/ILT4 DUAL
ANTAGONIST ANTIBODY, IN COMBINATION WITH MERCK’S KEYTRUDA®
(PEMBROLIZUMAB)
Source text for Eikon: ID:nGNXbbXwPh
Further company coverage: NGM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NGM Biopharmaceuticals
See all newsBrief: NGM Biopharmaceuticals Q4 Net Income USD -27.67 Million
Brief: NGM Bio Enters into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group
NGM Biopharmaceuticals Inc expected to post a loss of 39 cents a share - Earnings Preview
Brief: Ngm Biopharmaceuticals Says It Got Written Notice From Nasdaq Informing It Has Regained Compliance With Nasdaq Listing
Brief: NGM Bio Announces New Clinical Data From Ongoing Trial Of Ngm707 In Advanced Solid Tumors